Gilead Sciences

Biotech Innovations Paving the Way in Breast Cancer Fight

Retrieved on: 
Thursday, April 11, 2024
AstraZeneca, Breast cancer, Gilead Sciences, FDA, Radiation, University, PARP1, Cancer, Bone marrow, G1 Therapeutics, Paclitaxel, Protein, GILD, Safety, PARP, Pancreatic cancer, News, Progression-free survival, Survival, Estate (law), American Cancer Society, TSX, OS, Fast track (FDA), MBC, ONC, PETRA, Data monitoring committee, Rated R, Patient, Sacituzumab govitecan, Hologic, HOLX, Neoplasm, Death, DMC, AACR, Immune system, Type, TNBC, Trilaciclib, Pharmaceutical industry

VANCOUVER, BC, April 11, 2024 /PRNewswire/ -- USA News Group – The American Cancer Society is projecting 2024 to be the first year ever for the US to have more than 2 million new cases, which would represent a record high. Among 10 of the most common cancers, 6 have seen a rise in diagnoses, including the most common type of cancer in women—breast cancer. According to the World Health Organization breast cancer caused 670,000 deaths globally in 2022, and is predicting a 77% increase in new cancer cases by 2050. Based on the characteristics of each patient's tumor, how each patient is treated may be completely different from others. Broadening our ability to tackle breast cancer are several biotech developments including from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Gilead Sciences, Inc. (NASDAQ:GILD), G1 Therapeutics, Inc. (NASDAQ:GTHX), AstraZeneca PLC (NASDAQ:AZN), and Hologic, Inc. (NASDAQ:HOLX).

Key Points: 
  • According to the World Health Organization breast cancer caused 670,000 deaths globally in 2022 , and is predicting a 77% increase in new cancer cases by 2050 .
  • Broadening our ability to tackle breast cancer are several biotech developments including from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Gilead Sciences, Inc. (NASDAQ:GILD), G1 Therapeutics, Inc. (NASDAQ:GTHX), AstraZeneca PLC (NASDAQ:AZN), and Hologic, Inc. (NASDAQ:HOLX).
  • Coming off of a late-2022 FDA Fast Track Designation of Oncolytics Biotech Inc.'s (NASDAQ:ONCY) (TSX:ONC) flagship asset pelareorep for the treatment of pancreatic cancer, momentum is building towards another important FDA milestone, this time for breast cancer.
  • "We are optimistic that pelareorep, in combination with paclitaxel, could significantly enhance clinical outcomes for patients with HR+/HER2- metastatic breast cancer.

Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503

Retrieved on: 
Wednesday, April 10, 2024
Gilead Sciences, Safety, Compugen, Research, Immunotherapy, Tumor microenvironment, Cancer Immunology Research, Patient, BP, AACR, Neoplasm, Pharmaceutical industry

"There is a growing recognition of the importance of the IL-18 pathway in cancer immunology reflected in the surge in investment and collaboration in this space," said Anat Cohen-Dayag, Ph.D., President, and Chief Executive Officer of Compugen.

Key Points: 
  • "There is a growing recognition of the importance of the IL-18 pathway in cancer immunology reflected in the surge in investment and collaboration in this space," said Anat Cohen-Dayag, Ph.D., President, and Chief Executive Officer of Compugen.
  • Eran Ophir, Ph.D., Chief Scientific Officer at Compugen added, "Our paper published online yesterday in Cancer Immunology Research describes how COM503, a potential first-in-class high affinity monoclonal antibody, blocks the interaction between IL-18 and IL-18BP, unleashing the activity of endogenous IL-18 in the tumor.
  • Dr. Cohen-Dayag continued, "Combining the cutting-edge capabilities and expertise of both Compugen and Gilead, our goal is to expedite the development of COM503.
  • This year, we are progressing towards COM503 IND filing and are planning initiation of a Phase 1 study evaluating safety and tolerability of COM503."

Opthea Appoints Sujal Shah to the Board of Directors

Retrieved on: 
Wednesday, April 3, 2024
MB, Retina, Audit, Patient, Gilead Sciences, Therapy, AMD, Management

MELBOURNE, Australia and PRINCETON, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the appointment of Sujal Shah to the Company’s Board of Directors (the “Board”), effective April 4, 2024.

Key Points: 
  • MELBOURNE, Australia and PRINCETON, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the appointment of Sujal Shah to the Company’s Board of Directors (the “Board”), effective April 4, 2024.
  • Concurrent with his appointment as non-Executive Director, Mr. Shah will also become Chairman of the Audit and Risk Committee.
  • Mr. Shah is an accomplished biopharmaceutical executive with extensive leadership and product development experience and a track record in capital formation that complements the deep expertise in retinal disease, especially wet AMD, of the Opthea Board.
  • “We are delighted to welcome Sujal to our Board of Directors as we rapidly advance the registrational program for sozinibercept in wet AMD and prepare for key upcoming clinical, regulatory and commercial milestones,” said Jeremy Levin, D.Phil, MB BChir, Chairman of the Opthea Board of Directors.

Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences

Retrieved on: 
Tuesday, April 2, 2024
Therapy, Patient, SAN, Gilead Sciences, Research, Rheumatoid arthritis, Cancer, IRAK4, Inflammation, Pharmaceutical industry

SAN FRANCISCO, April 02, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Gilead Sciences has elected to extend the research term of the companies’ ongoing collaboration, originally established in 2019, by an additional two years.

Key Points: 
  • “Gilead’s extension of the research period of this agreement is a testament to the productivity of our collaboration to date.
  • Most importantly, it increases the opportunity for additional clinical candidates and associated milestones to emerge from our work together with the Gilead team,” said Gwenn M. Hansen, Ph.D., chief scientific officer of Nurix.
  • Gilead has an option to license drug candidates resulting from the work, and Nurix retains co-development and co-detail options on up to two programs in the United States, subject to certain restrictions.
  • Upon signing the agreement in 2019, Gilead made an upfront payment of $45.0 million.

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Monday, April 1, 2024
FC, TME, Administration, Cell, Partnership, Patient, Gilead Sciences, Pharming, Research, Tumor microenvironment, G&A, Cancer, PacWest Bancorp, AACR, MSS, Investment, Therapy, CRC, Safety, Workforce, PD-1, Pharmaceutical industry

WALTHAM, Mass., April 01, 2024 (GLOBE NEWSWIRE) --  Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced pipeline progress and business updates and reported financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Xilio today reaffirmed plans to:
    Select a recommended Phase 2 dose for XTX101 in combination with atezolizumab in the second quarter of 2024.
  • In March 2024, Xilio and Gilead Sciences, Inc. (Gilead) announced an exclusive license agreement for Xilio’s tumor-activated IL-12 program, including XTX301.
  • Xilio will also be eligible to receive tiered royalties ranging from high single digits to mid-teens on annual global net product sales.
  • Net Loss: Net loss was $17.7 million for the quarter ended December 31, 2023, compared to $22.5 million for the quarter ended December 31, 2022.

Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing

Retrieved on: 
Thursday, March 28, 2024
FC, Exchange, Partnership, Patient, Gilead Sciences, Pharming, Research, Sale, Cancer, PacWest Bancorp, Security (finance), Prospectus, Investment, RCC, Therapy, Safety, Melanoma, Workforce, IL-12, PacWest, Pharmaceutical industry

WALTHAM, Mass., March 28, 2024 (GLOBE NEWSWIRE) --  Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that it has entered into a securities purchase agreement with certain existing accredited investors, including Bain Capital Life Sciences and Rock Springs Capital, to issue and sell an aggregate of 1,953,125 shares of Xilio common stock at a price of $0.64 per share and prefunded warrants to purchase up to an aggregate of 15,627,441 shares of Xilio common stock at a purchase price of $0.6399 per prefunded warrant share, through a private investment in public equity financing. The prefunded warrants will have an exercise price of $0.0001 per share of common stock, be immediately exercisable and remain exercisable until exercised in full. Xilio anticipates receiving aggregate gross proceeds from the private placement of approximately $11.3 million, before deducting placement agent fees and expenses payable by the company. The private placement is expected to close on April 2, 2024, subject to the satisfaction of customary closing conditions. Xilio expects to use the proceeds from the private placement to fund working capital and other general corporate purposes.

Key Points: 
  • Xilio anticipates receiving aggregate gross proceeds from the private placement of approximately $11.3 million, before deducting placement agent fees and expenses payable by the company.
  • The private placement is expected to close on April 2, 2024, subject to the satisfaction of customary closing conditions.
  • Xilio expects to use the proceeds from the private placement to fund working capital and other general corporate purposes.
  • Prior to the potential transition fee, Xilio is eligible to receive up to a total of $29.0 million in additional equity investments and a development milestone payment.

Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program

Retrieved on: 
Thursday, March 28, 2024
Molecule, Therapeutic index, EPS, Gilead Sciences, Patient, Pharming, Tumor microenvironment, Doctor of Philosophy, MD, Senior, IPR, Investment, Therapy, Antibody, Cytokine, IL-12, Pharmaceutical industry

FOSTER CITY, Calif. and WALTHAM, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Gilead Sciences, Inc. (Nasdaq: GILD) and Xilio Therapeutics, Inc. (Nasdaq: XLO) today announced an exclusive license agreement to develop and commercialize Xilio’s Phase 1 tumor-activated IL-12 program, XTX301.

Key Points: 
  • -- Gilead Granted Exclusive License to Xilio’s Tumor-Activated IL-12 Program, Including XTX301, a Clinical-Stage IL-12 Molecule with Potential to Treat a Broad Range of Cancers --
    FOSTER CITY, Calif. and WALTHAM, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Gilead Sciences, Inc. (Nasdaq: GILD) and Xilio Therapeutics, Inc. (Nasdaq: XLO) today announced an exclusive license agreement to develop and commercialize Xilio’s Phase 1 tumor-activated IL-12 program, XTX301.
  • XTX301 is currently being evaluated in a Phase 1 dose escalation trial in patients with advanced solid tumors.
  • Xilio will receive $43.5 million in upfront payments, including a cash payment of $30.0 million and an initial equity investment by Gilead of $13.5 million in Xilio common stock at a premium.
  • Xilio will be responsible for conducting clinical development of XTX301 in the ongoing Phase 1 clinical trial through dose expansion.

HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Friday, March 22, 2024
SIV, Clinical trial, Hepatitis, Head, CPI, Serum, Hepatitis B, Partnership, HIV, Oncology, Gilead Sciences, Patient, Lung, Journal, Viral load, Pembrolizumab, HBV, Trial of the century, IND, Infection, Hepatocyte, Arenavirus, Antibody, Vaccination, Intellectual property, FDA, Liver, Animal, Pharmaceutical industry

“It was a defining year for HOOKIPA as we witnessed the powerful potential of our novel arenaviral immunotherapies in action.

Key Points: 
  • “It was a defining year for HOOKIPA as we witnessed the powerful potential of our novel arenaviral immunotherapies in action.
  • Data was initially presented in May 2023 and additional patient data was provided in October at the European Society for Medical Oncology Congress 2023.
  • HOOKIPA expects to initiate a Phase 1 clinical study of HB-500 in people with HIV in the second quarter of 2024.
  • In June 2023, the Company completed a $50.0 million public offering of common stock and non-voting convertible preferred stock.

Global Cell and Gene Therapy Markets Report 2024-2028: Focus on Zolgensma, Yescarta, Kymriah, Abecma, Maci, Tecartus, Epicel - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 3, 2024
Health, Genetics, Growth, PTC Therapeutics, Prevalence, Gene editing, ESG, CSL Behring, Roche, Etranacogene dezaparvovec, Gene, Gilead Sciences, Cancer, Eladocagene exuparvovec, Therapy, CRISPR, Mallinckrodt, PTC, Probability, BLA, Pharmaceutical industry

The "Global Cell and Gene Therapy Market" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Cell and Gene Therapy Market" report has been added to ResearchAndMarkets.com's offering.
  • The Global Cell and Gene Therapy Market is expected to grow at a compound annual growth rate (CAGR) of 26.40% from 2023 through 2028.
  • The scope of this study encompasses an investigation of the cell and gene therapy market.
  • The report analyzes cell and gene therapy market based on therapy type, product, application, and region.

Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program

Retrieved on: 
Thursday, March 28, 2024
Oncology, Health, Hospitals, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Therapeutic index, EPS, Patient, Gilead Sciences, Pharming, Tumor microenvironment, Science, Doctor of Philosophy, MD, Senior, IPR, Investment, Therapy, Cancer, Antibody, Cytokine, IL-12, Multimedia, Pharmaceutical industry

Gilead Sciences, Inc. (Nasdaq: GILD) and Xilio Therapeutics, Inc. (Nasdaq: XLO) today announced an exclusive license agreement to develop and commercialize Xilio’s Phase 1 tumor-activated IL-12 program, XTX301.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) and Xilio Therapeutics, Inc. (Nasdaq: XLO) today announced an exclusive license agreement to develop and commercialize Xilio’s Phase 1 tumor-activated IL-12 program, XTX301.
  • View the full release here: https://www.businesswire.com/news/home/20240328734624/en/
    Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies.
  • Xilio will receive $43.5 million in upfront payments, including a cash payment of $30 million and an initial equity investment by Gilead of $13.5 million in Xilio common stock at a premium.
  • Xilio will be responsible for conducting clinical development of XTX301 in the ongoing Phase 1 clinical trial through dose expansion.